Stock VLAP VALNEVA SE PREF.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Valneva SE Pref. Euronext Paris

Equities

VLAP

FR0011472943

Real-time Euronext Paris
Other stock markets
 		5-day change 1st Jan Change
- EUR -.--% Intraday chart for Valneva SE Pref. -7.89% -28.57%
May. 22 Valneva Se Appoints Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer CI
May. 21 Valneva Names New Chief Scientific Officer MT

Summary

  • The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

  • The prospective high growth for the next fiscal years is among the main assets of the company
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • For several months, analysts have been revising their EPS estimates roughly upwards.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

  • The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • The company has insufficient levels of profitability.
  • One of the major weak points of the company is its financial situation.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
VALNEVA SE PREF. Stock Valneva SE Pref.
-28.57% 586M -
MODERNA, INC. Stock Moderna, Inc.
+67.53% 63.85B
B-
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-0.77% 41.83B
B
LONZA GROUP AG Stock Lonza Group AG
+45.66% 40.65B
A
CELLTRION, INC. Stock Celltrion, Inc.
-10.72% 27.12B
C
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+13.30% 26.52B
B-
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-22.79% 18.69B
B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+4.70% 12.73B
B+
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+24.10% 12.11B
B+
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.41% 12.07B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. VLA Stock
  4. VLAP Stock
  5. Ratings Valneva SE Pref.